Dl-Penicillamine

Dl-Penicillamine

SCHEMBL159653

CC(C)(S)[C@H](N)C(=O)O.CC(C)(S)[C@H](N)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 1.00
PTGS1 P23219 2/20 1.00
MAPT P10636 2/20 1.00
SLC7A5 Q01650 2/20 0.38
SLC7A11 Q9UPY5 1/20 0.36
ENPEP Q07075 3/20 0.33
GRIK1 P39086 1/20 0.33
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32
SLC1A1 P43005 1/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
ABCB11 O95342 1/20 0.32
F2 P00734 1/20 0.32
TP53 P04637 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALOX15 P16050 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Penicillamine SCHEMBL4344 1.00
Penicillamine SCHEMBL4343 1.00
Dl-Penicillamine SCHEMBL57527 1.00
Penicillamine SCHEMBL129296 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1MAPTSLC7A5SLC7A11
Penicillamine SCHEMBL603349 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1MAPTSLC7A5SLC7A11
Dl-Penicillamine SCHEMBL22322162 1.00 ALDH1A1 (1.00) ALDH1A1PTGS1MAPTSLC7A5SLC7A11
Penicillamine SCHEMBL10789333 0.97 ALDH1A1 (0.95) ALDH1A1PTGS1MAPTSLC7A5SLC7A11
Penicillamine SCHEMBL3138111 0.97 ALDH1A1 (0.95) ALDH1A1PTGS1MAPTSLC7A5SLC7A11
Penicillamine SCHEMBL6654084 0.97
Penicillamine SCHEMBL7932147 0.97 ALDH1A1 (0.95) ALDH1A1PTGS1MAPTSLC7A5SLC7A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5445945-A Methods of regenerating metalworking fluids with chelating agents THE TORRINGTON COMPANY (US) 1995-08-29 US claimed
US-8679825-B2 Method facilitating removal of bioorganic stains from surfaces TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2014-03-25 US disclosed
US-20120065137-A1 THERAPEUTICS FOR TRAUMA INDUCED FACTOR V CONSUMPTIVE COAGULOPATHY JENNY RICHARD (US) 2012-03-15 US disclosed
US-20120034638-A1 Electrochemical assay for the detection of enzymatically active PSA NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION 2012-02-09 US disclosed
US-20120028897-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS IRONWOOD PHARMACEUTICALS 2012-02-02 US disclosed
WO-2011163237-A2 CLEARCOAT CONTAINING THERMOASE C160® FOR EASY-CLEANING OF INSECT BODY STAINS TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2011-12-29 WO disclosed
WO-2011163257-A2 LIPASE-CONTAINING POLYMERIC COATINGS FOR THE FACILITATED REMOVAL OF FINGERPRINTS TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2011-12-29 WO disclosed
WO-2011146143-A2 DETECTION OF CANCER BY ASSAYING PSA ENZYMATIC ACTIVITY OHMX CORPORATION (US) 2011-11-24 WO disclosed
WO-2011146521-A2 A GENERAL MASS SPECTROMETRY ASSAY USING CONTINUOUSLY ELUTING CO-FRACTIONATING REPORTERS OF MASS SPECTROMETRY DETECTION EFFICIENCY THE UAB RESEARCH FOUNDATION (US) 2011-11-24 WO disclosed
US-20110282029-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR AFFYMAX, INC. (US) 2011-11-17 US disclosed
EP-2370087-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS Ironwood Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2011100408-A2 SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) 2011-08-18 WO disclosed
US-20110076738-A1 SOLVENT-BORNE POLYMERIC BIOACTIVE COATINGS FOR THE FACILITATED REMOVAL OF BIOORGANIC STAINS Toyota Motor Engineering & Manufacturing North America, Inc (US) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282029-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR EPOR, PROKR1, EDNRB ALDH1A1 4119/4885PTGS1 3169/4885MAPT 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.